1-(5-Ethyl-3-methylpyridin-2-yl)piperazine → HCID 71252575, Verbindung

HRID 2411613Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 2411613
[O:1]=[S:2]1(=[O:18])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:16]=[CH:15][C:10]([C:11]([O:13]C)=O)=[C:9]([CH3:17])[N:8]=1.[CH2:19]([C:21]1[CH:22]=[C:23]([CH3:33])[C:24]([N:27]2[CH2:32][CH2:31][NH:30][CH2:29][CH2:28]2)=[N:25][CH:26]=1)[CH3:20]>>[O:18]=[S:2]1(=[O:1])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[N:8]=[C:9]([CH3:17])[C:10]([C:11]([N:30]2[CH2:31][CH2:32][N:27]([C:24]3[C:23]([CH3:33])=[CH:22][C:21]([CH2:19][CH3:20])=[CH:26][N:25]=3)[CH2:28][CH2:29]2)=[O:13])=[CH:15][CH:16]=1

Komponenten

3

Edukt 2

HCID 584845781-(5-Ethyl-3-methylpyridin-2-yl)piperazineHCID 71252256HCID 71252256, Verbindung

Produkt 1

HCID 71252575HCID 71252575, VerbindungAusbeute 5,1 %

Versuchsvorschrift

Using methyl 6-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-2-methylnicotinate (300 mg) described in Preparation Example 37 and 1-(5-ethyl-3-methylpyridin-2-yl)piperazine (251 mg) described in Preparation Example 81 and by the reaction and treatment in the same manner as in Example 109, the title compound (25 mg) was obtained.

Aufarbeitung

  1. customdescribed in Preparation Example 81 and by the reaction and treatment in the same manner as in Example 109

Quellen und Nachweise

ORD-Eintrag
ord-f1716edaabfa4f969169ae9e6915e255
Quelldatensatz
uspto-grants-2014_08
Patentnummer
US08816079B2

Notizen zur Reaktion

Wird geladen…